Physician profile
John Baugh
NPI 1942208707
$9,303.51
in general payments reported to CMS, 2019-2025
34 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.26 · 2020: $172 · 2021: $811 · 2022: $1,682 · 2023: $2,408 · 2024: $2,203 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,621.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,556.76 | 2020-2025 | |
| Amgen INC. | $906.74 | 2020-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $766.12 | 2020-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $717.06 | 2021-2025 | Cds - Mct/Cem Monitoring, Watchman Access System, Bodyguardian |
| Janssen Pharmaceuticals, INC | $680.19 | 2021-2024 | Xarelto |
| Pfizer INC. | $657.11 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $490.45 | 2021-2025 | Farxiga, Brilinta, Wainua |
| Philips North America LLC | $488.00 | 2020-2025 | (Ck4) Mcot, Event, Extended Holter |
| Esperion Therapeutics, INC. | $482.07 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $398.72 | 2022-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $398.00 | 2022-2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $275.85 | 2022-2025 | |
| Abbott Laboratories | $267.05 | 2021-2025 | Aveir, Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.08 | 2022-2025 | Jardiance |
| Scpharmaceuticals INC. | $171.21 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $144.82 | 2023-2025 | Micra, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.40 | 2020-2024 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $98.10 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $67.70 | 2022-2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $66.54 | 2024 | Uptravi, Opsumit |
| Arbor Pharmaceuticals, INC. | $50.70 | 2021 | |
| Daiichi Sankyo INC. | $41.79 | 2023 | Injectafer |
| Chiesi USA, INC. | $41.22 | 2023 | Kengreal |
| Lexicon Pharmaceuticals, INC. | $39.90 | 2023-2024 | Inpefa |
| Cvrx, INC. | $28.68 | 2024-2025 | Barostim Neo System |
| Jazz Pharmaceuticals INC. | $28.37 | 2025 | |
| Abiomed | $25.12 | 2024 | Impella |
| Impulse Dynamics (USA) INC. | $21.76 | 2023 | Optimizer |
| Genzyme Corporation | $21.71 | 2023 | |
| Cardiva Medical, INC. | $19.21 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.03 | 2024 | Evkeeza, Praluent |
| Biotronik INC. | $17.26 | 2019 | |
| Lilly USA, LLC | $14.81 | 2025 | Zepbound, Mounjaro |
| Edwards Lifesciences Corporation | $12.98 | 2023 | Sapien 3 Ultra Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Baugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.